Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, et al.
Journal of the National Comprehensive Cancer Network (2016) Vol. 15, Iss. 1, pp. 60-87
Open Access | Times Cited: 282

Showing 1-25 of 282 citing articles:

Next-generation sequencing and its clinical application
Dahui Qin
Cancer Biology and Medicine (2019) Vol. 16, Iss. 1, pp. 4-10
Open Access | Times Cited: 229
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini, António Almeida, Aristoteles Giagounidis, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 25, pp. 2988-2996
Closed Access | Times Cited: 207
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma, et al.
Blood (2020) Vol. 136, Iss. 6, pp. 674-683
Open Access | Times Cited: 175
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Guillermo Garcia‐Manero, Kelly S. Chien, Guillermo Montalban‐Bravo
American Journal of Hematology (2020) Vol. 95, Iss. 11, pp. 1399-1420
Open Access | Times Cited: 164
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment
Oriana Miltiadous, Ming Hou, James B. Bussel
Blood (2019) Vol. 135, Iss. 7, pp. 472-490
Open Access | Times Cited: 151
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Martha Dillon, Antonio R. Lopez, Edward H. Lin, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5059-5059
Open Access | Times Cited: 109
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 94
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Adès, Larisa Girshova, Vadim Doronin, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 5132-5145
Open Access | Times Cited: 80
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Amer M. Zeidan, Rory M. Shallis, Rong Wang, et al.
Blood Reviews (2018) Vol. 34, pp. 1-15
Closed Access | Times Cited: 155
Myelodysplastic syndromes current treatment algorithm 2018
David P. Steensma
Blood Cancer Journal (2018) Vol. 8, Iss. 5
Open Access | Times Cited: 151
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Leukemia (2018) Vol. 32, Iss. 12, pp. 2648-2658
Open Access | Times Cited: 142
Myelodysplastic syndromes: moving towards personalized management
Eva Hellström‐Lindberg, Magnus Tobiasson, Peter L. Greenberg
Haematologica (2020) Vol. 105, Iss. 7, pp. 1765-1779
Open Access | Times Cited: 108
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarhan, Ludwig Brandt, Martin Felices, et al.
Blood Advances (2018) Vol. 2, Iss. 12, pp. 1459-1469
Open Access | Times Cited: 99
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
Amy E. DeZern, Luca Malcovati, Benjamin L. Ebert
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 400-410
Closed Access | Times Cited: 79
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages
Simone Feurstein, Amy M. Trottier, Noel Estrada‐Merly, et al.
Blood (2022) Vol. 140, Iss. 24, pp. 2533-2548
Open Access | Times Cited: 69
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
Aziz Nazha, Rami S. Komrokji, Manja Meggendorfer, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 33, pp. 3737-3746
Open Access | Times Cited: 65
Myelodysplastic syndromes
Huan Li, Fang‐Wen Hu, Robert Peter Gale, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 46
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
Hyo Song Kim, Minkyu Jung, H.N. Kang, et al.
Oncogene (2017) Vol. 36, Iss. 23, pp. 3334-3345
Closed Access | Times Cited: 86
The genetic and molecular pathogenesis of myelodysplastic syndromes
Rory M. Shallis, Rami Ahmad, Amer M. Zeidan
European Journal Of Haematology (2018) Vol. 101, Iss. 3, pp. 260-271
Open Access | Times Cited: 71
Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia
Pallavi Galera, Alina Dulau‐Florea, Katherine R. Calvo
International Journal of Laboratory Hematology (2019) Vol. 41, Iss. S1, pp. 131-141
Open Access | Times Cited: 59
Development of luspatercept to treat ineffective erythropoiesis
Anne Sophie Kubasch, Pierre Fenaux, Uwe Platzbecker
Blood Advances (2021) Vol. 5, Iss. 5, pp. 1565-1575
Open Access | Times Cited: 55
Germline variants drive myelodysplastic syndrome in young adults
Simone Feurstein, Jane E. Churpek, Tom Walsh, et al.
Leukemia (2021) Vol. 35, Iss. 8, pp. 2439-2444
Open Access | Times Cited: 53
The Clinical Management of Clonal Hematopoiesis
Kelly L. Bolton, Ahmet Zehir, Ryan Ptashkin, et al.
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 2, pp. 357-367
Closed Access | Times Cited: 51
Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
Fanqiao Meng, Lijuan Li, Fengzhu Lu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 51
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis
Jia Chen, Ailin Zhao, Minghui Duan, et al.
Leukemia (2021) Vol. 36, Iss. 2, pp. 573-576
Closed Access | Times Cited: 43
Page 1 - Next Page

Scroll to top